Literature DB >> 17025237

Osmotic flow through asymmetric membrane: a means for controlled delivery of drugs with varying solubility.

Anil K Philip1, Kamla Pathak.   

Abstract

A nondisintegrating, controlled release, asymmetric membrane capsular system of flurbiprofen was developed and evaluated for controlled release of the drug to overcome some of its side effects. Asymmetric membrane capsules were prepared using fabricated glass mold pins by phase inversion process. The effect of different formulation variables was studied based on 2(3) factorial design; namely, level of osmogen, membrane thickness, and level of pore former. Effects of polymer diffusibility and varying osmotic pressure on drug release were also studied. Membrane characterization by scanning electron microscopy showed an outer dense region with less pores and an inner porous region for the prepared asymmetric membrane. Differential scanning calorimetry studies showed no incompatibility between the drug and the excipients used in the study. In vitro release studies for all the prepared formulations were done (n = 6). Statistical test (Dunnett multiple comparison test) was applied for in vitro drug release at P > .05. The best formulation closely corresponded to the extra design checkpoint formulation by a similarity (f2) value of 92.94. The drug release was independent of pH but dependent on the osmotic pressure of the dissolution medium. The release kinetics followed the Higuchi model and the mechanism of release was Fickian diffusion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17025237      PMCID: PMC2750498          DOI: 10.1208/pt070356

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  9 in total

1.  Elementary osmotic pump.

Authors:  F Theeuwes
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  MECHANISM OF SUSTAINED-ACTION MEDICATION. THEORETICAL ANALYSIS OF RATE OF RELEASE OF SOLID DRUGS DISPERSED IN SOLID MATRICES.

Authors:  T HIGUCHI
Journal:  J Pharm Sci       Date:  1963-12       Impact factor: 3.534

3.  Investigations on the drug releasing mechanism from an asymmetric membrane-coated capsule with an in situ formed delivery orifice.

Authors:  Ying Ku Lin; Hsiu O Ho
Journal:  J Control Release       Date:  2003-04-14       Impact factor: 9.776

4.  Asymmetric membrane capsules for osmotic drug delivery II. In vitro and in vivo drug release performance.

Authors:  A G Thombre; J R Cardinal; A R DeNoto; D C Gibbes
Journal:  J Control Release       Date:  1999-01-04       Impact factor: 9.776

5.  Asymmetric membrane capsules for osmotic drug delivery. I. Development of a manufacturing process.

Authors:  A G Thombre; J R Cardinal; A R DeNoto; S M Herbig; K L Smith
Journal:  J Control Release       Date:  1999-01-04       Impact factor: 9.776

6.  The solubility-modulated osmotic pump: in vitro/in vivo release of diltiazem hydrochloride.

Authors:  G A McClelland; S C Sutton; K Engle; G M Zentner
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

7.  Investigation of factors influencing release of solid drug dispersed in inert matrices. 3. Quantitative studies involving the polyethylene plastic matrix.

Authors:  S J Desai; P Singh; A P Simonelli; W I Higuchi
Journal:  J Pharm Sci       Date:  1966-11       Impact factor: 3.534

8.  The effect of pre-operative topical flurbiprofen or diclofenac on pupil dilatation.

Authors:  V T Thaller; M K Kulshrestha; K Bell
Journal:  Eye (Lond)       Date:  2000-08       Impact factor: 3.775

Review 9.  A review of selected investigational nonsteroidal antiinflammatory drugs of the 1980s.

Authors:  C C Marsh; A A Schuna; W R Sundstrom
Journal:  Pharmacotherapy       Date:  1986 Jan-Feb       Impact factor: 4.705

  9 in total
  10 in total

1.  Solubility-modulated asymmetric membrane tablets of triprolidine hydrochloride: statistical optimization and evaluation.

Authors:  Rahul Dev; Anil Kumar; Kamla Pathak
Journal:  AAPS PharmSciTech       Date:  2011-12-20       Impact factor: 3.246

2.  Colon targeted drug delivery systems: a review on primary and novel approaches.

Authors:  Anil K Philip; Betty Philip
Journal:  Oman Med J       Date:  2010-04

Review 3.  Colon-targeted oral drug delivery systems: design trends and approaches.

Authors:  Seth Amidon; Jack E Brown; Vivek S Dave
Journal:  AAPS PharmSciTech       Date:  2015-06-13       Impact factor: 3.246

4.  Phase transited asymmetric membrane floating nanoparticles: a means for better management of poorly water-soluble drugs.

Authors:  Betty Annie Samuel; Bassim I Mohammed; Anil K Philip
Journal:  Daru       Date:  2021-08-20       Impact factor: 4.088

5.  Osmotically regulated floating asymmetric membrane capsule for controlled site-specific delivery of ranitidine hydrochloride: optimization by central composite design.

Authors:  Manvendra S Chauhan; Anil Kumar; Kamla Pathak
Journal:  AAPS PharmSciTech       Date:  2012-10-27       Impact factor: 3.246

6.  In situ formed phase transited drug delivery system of ketoprofen for achieving osmotic, controlled and level a in vitro in vivo correlation.

Authors:  A K Philip; Kamla Pathak
Journal:  Indian J Pharm Sci       Date:  2008-11       Impact factor: 0.975

7.  Osmotically regulated two-compartment asymmetric membrane capsules for simultaneous controlled release of anti-hypertensive drugs.

Authors:  Saurabh Garg; Kamla Pathak; Anil Philip; Dinesh Puri
Journal:  Sci Pharm       Date:  2011-12-23

8.  Cellulose Acetate 398-10 Asymmetric Membrane Capsules for Osmotically Regulated Delivery of Acyclovir.

Authors:  Alka Sonkar; Anil Kumar; Kamla Pathak
Journal:  J Pharm (Cairo)       Date:  2016-02-11

9.  Asymmetric membrane osmotic capsules for terbutaline sulphate.

Authors:  N G Gobade; Marina Koland; K H Harish
Journal:  Indian J Pharm Sci       Date:  2012-01       Impact factor: 0.975

10.  Dexamethasone implant in silicone oil: in vitro behavior.

Authors:  Erick Omar Flores-Villalobos; J Abel Ramírez-Estudillo; Atzin Robles-Contreras; Jacqueline L Oliva-Ramírez
Journal:  Int J Retina Vitreous       Date:  2018-06-20
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.